| Pharmacogenetic approaches to the treatment of alcohol addiction. | |
| | |
MedLine Citation:
|
PMID: 22011682 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
Addictive disorders are partly heritable, chronic, relapsing conditions that account for a tremendous disease burden. Currently available addiction pharmacotherapies are only moderately successful, continue to be viewed with considerable scepticism outside the scientific community and have not become widely adopted as treatments. More effective medical treatments are needed to transform addiction treatment and address currently unmet medical needs. Emerging evidence from alcoholism research suggests that no single advance can be expected to fundamentally change treatment outcomes. Rather, studies of opioid, corticotropin-releasing factor, GABA and serotonin systems suggest that incremental advances in treatment outcomes will result from an improved understanding of the genetic heterogeneity among patients with alcohol addiction, and the development of personalized treatments. |
| | |
Authors:
|
Markus Heilig; David Goldman; Wade Berrettini; Charles P O'Brien |
Publication Detail:
|
Type: Journal Article; Research Support, N.I.H., Extramural; Research Support, N.I.H., Intramural; Review Date: 2011-10-20 |
Journal Detail:
|
Title: Nature reviews. Neuroscience Volume: 12 ISSN: 1471-0048 ISO Abbreviation: Nat. Rev. Neurosci. Publication Date: 2011 Nov |
Date Detail:
|
Created Date: 2011-10-20 Completed Date: 2011-12-08 Revised Date: 2012-01-27 |
Medline Journal Info:
|
Nlm Unique ID: 100962781 Medline TA: Nat Rev Neurosci Country: England |
Other Details:
|
Languages: eng Pagination: 670-84 Citation Subset: IM |
Affiliation:
|
Laboratory of Clinical and Translational Studies, National Institute on Alcohol Abuse and Alcoholism, National Institutes of Health, Bethesda, Maryland 20892, USA. markus.heilig@mail. nih.gov |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Alcoholism
/
drug therapy*,
genetics* Analgesics, Opioid / therapeutic use Humans Pharmacogenetics* Polymorphism, Single Nucleotide Receptors, Opioid / genetics* |
| Grant Support | |
ID/Acronym/Agency:
|
5-P50-DA- 012756-11/DA/NIDA NIH HHS; P20-DA-025995/DA/NIDA NIH HHS; P60-DA 05186/DA/NIDA NIH HHS; P60-DA-005186-23/DA/NIDA NIH HHS; R01-AA017164-2/AA/NIAAA NIH HHS; R01-DA-024553/DA/NIDA NIH HHS; R01-DA-025201/DA/NIDA NIH HHS |
| Chemical | |
Reg. No./Substance:
|
0/Analgesics, Opioid; 0/Receptors, Opioid |
| Comments/Corrections | |
Comment In:
|
Nat Rev Neurosci. 2011;13(1):70; author reply 70
[PMID:
22183439
]
|
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Dysfunction of the prefrontal cortex in addiction: neuroimaging findings and clinical implications.
Next Document: Association of renal function with the ambulatory arterial stiffness index and pulse pressure in hyp...